BEKEMV Trademark

Trademark Overview


On Wednesday, March 2, 2022, a trademark application was filed for BEKEMV with the United States Patent and Trademark Office. The USPTO has given the BEKEMV trademark a serial number of 97290948. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 19, 2024. This trademark is owned by Amgen Inc.. The BEKEMV trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and substances for use in the treatment of hematological, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure
bekemv

General Information


Serial Number97290948
Word MarkBEKEMV
Filing DateWednesday, March 2, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 24, 2022

Trademark Statements


Goods and Servicespharmaceutical preparations and substances for use in the treatment of hematological, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 7, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Thursday, April 14, 2022ASSIGNED TO EXAMINER
Saturday, March 5, 2022NEW APPLICATION ENTERED
Monday, March 7, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 19, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 24, 2022PUBLISHED FOR OPPOSITION
Wednesday, May 4, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 24, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 19, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 12, 2022SOU TEAS EXTENSION RECEIVED
Monday, December 12, 2022SOU EXTENSION 1 FILED
Monday, December 12, 2022SOU EXTENSION 1 GRANTED
Wednesday, December 14, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 8, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 18, 2023SOU EXTENSION 2 FILED
Tuesday, July 18, 2023SOU EXTENSION 2 GRANTED
Thursday, July 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 19, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, August 19, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 8, 2024SOU EXTENSION 3 GRANTED
Monday, January 8, 2024SOU EXTENSION 3 FILED